Replies to post #4470 on Xenacare Holdings Inc.(fka XCHO)

[geodan]

SL, I am more positive now than was after the pre-10Q PR, which was quite the bummer.

We are both learning thru this process, it is unfortunate that some posters can not disagree without maintaining perspective and civility as you are able to do. This board is actually pretty good in that way, thus the company, the investment potential and the facts are focused on not the posters.

BTW was just going thru the NPHC #s now again on the expense side.


Salaries and employee benefits 330,284 127,676 587,717 254,902
Selling, general and administrative - including stock based compensation of $398,750, $195,000, $505,000 and $215,000, respectively 1,003,932 316,787 1,441,161 441,903
Research and development 102,435 55,155 157,248 125,375
Interest expense 12,847 17,965 26,036 34,286
Total costs and expenses 1,449,498 517,583 2,212,162 856,466

It did not format right on paste so here is source http://ih.advfn.com/p.php?pid=nmona&article=44026380&symbol=NB^NPHC

What I see is Salaries being 330k, R&D $102K and Selling, general and administrative - including stock based compensation of $398,750, being $1,003,932

They do not have selling expense, so it looks like pure G&A (overhead) is about $600k cash and $399k stock. So that is $1.003 million for 3 months for how many people outside of R&D and outside the other $330k of salaries? That is where the cash is going for NPHC. I can not find the detail in the report to explain that.

Cheers